Navigation Links
PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies

BIRMINGHAM, Ala., March 10, 2011 /PRNewswire/ -- PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham (UAB) — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer.

"A number of important regulatory and financial efforts came to fruition, enabling PNP Therapeutics to begin a crucial phase in product development," said Frank R. Hunt, chief executive officer of PNP Therapeutics, Inc.   "We are delighted that we accomplished these goals so we can continue moving our technology products forward."

According to Hunt, those objectives included:

  • Receiving FDA approval of its Investigational New Drug (IND) application which will now allow PNP to conduct its first-in-man studies;
  • Signing an agreement with UAB to conduct clinical trials at its Comprehensive Cancer Center;
  • Enrolling and treating the first clinical trials patient;
  • Closing on a second round of funding worth $1,217,635 from its original investors;
  • Gaining a commitment from Southern Research Institute to become a direct investor in the company; and
  • Being awarded a $245,000 grant from the federal government as part of its Qualifying Therapeutic Discovery Project.

At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) which has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity. PNP Therapeutics is the exclusive licensee of a comprehensive collection of patents that broadly and specifically cover the Company's technology. These patents are owned jointly by the University of Alabama at Birmingham Research Foundation and Southern Research Institute of Birmingham.


Many common cancers can become untreatable despite the best medical intervention and the highest standard of care; some are eventually fatal. Compounds that could kill tumors are typically much too toxic to administer systemically to an already debilitated cancer patient.

PNP's therapeutic strategy is based on the notion that solid tumors can be programmed to generate their own chemotherapy, causing their own self-destruction. This selectivity is achieved by producing the PNP enzyme directly within the tumor cells and facilitating the interaction between the enzyme and a circulating prodrug in a relatively enclosed environment — the tumor mass itself.

"We have shown that this mode of chemotherapeutic action is remarkably potent, abolishes otherwise refractory human cancers, and can be used safely because it is executed and confined within the tumor mass," said Hunt.

Persons interested in learning more about this PNP Therapeutics clinical trial can access the information at


PNP Therapeutics®, Inc. is an early-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer.   To learn more, please contact Frank Hunt at or call 706-636-3049.

SOURCE PNP Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics to Present at the ROTH 23rd Annual Growth Stock Conference
2. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
3. Allon Therapeutics CEO Presentation Now Available for On-Demand Viewing at
4. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
5. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
6. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
7. Nile Therapeutics Receives Positive NASDAQ Panel Decision
8. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk
9. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Echo Therapeutics Receives Frost & Sullivans 2011 Technology Innovation Award
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):